- Home
- CCS vs ZLAB Comparison
CCS vs ZLAB Comparison
Compare CCS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCS | ZLAB |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CCS | ZLAB |
|---|---|---|
| Price | $60.30 | $18.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $70.50 | $57.22 |
| AVG Volume (30 Days) | 240.3K | ★ 810.7K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | ★ $4,157,669,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | $8.74 | $34.71 |
| P/E Ratio | $8.73 | ★ N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $50.42 | $18.61 |
| 52 Week High | $88.41 | $44.34 |
Technical Indicators
Market Signals| Indicator | CCS | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 21.76 |
| Support Level | $63.69 | $19.40 |
| Resistance Level | $67.10 | $20.22 |
| Average True Range (ATR) | 2.10 | 0.53 |
| MACD | -0.03 | 0.20 |
| Stochastic Oscillator | 38.97 | 5.02 |
Price Performance
Historical ComparisonAbout CCS Century Communities Inc.
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.